Area of research
Immunology · Oncology
Research interest
Research interests include Inflammation biomarkers and pathways, Immune Cell Function and Interaction, Immune cells in cancer, and CAR-T cell therapy research.
ZEB2 is a master switch controlling the tumor-associated macrophage program
Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy
Dissection of the immune landscape in psoriatic arthritis defines immunoproteasome up-regulation in treatment resistance
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols
The transcriptional and regulatory identity of erythropoietin producing cells
LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma
High mannose level in bladder cancer enhances type 1 fimbria–mediated attachment of uropathogenic E. coli
Native aortic valve <i>Staphylococcus warneri</i> endocarditis after COVID‐19 infection: a case report and a review of literature
Publisher Correction: XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
<i>Fusobacterium nucleatum</i> supresses anti-tumor immunity by activating CEACAM1
High percentages and activity of synovial fluid NK cells present in patients with advanced stage active Rheumatoid Arthritis
The <i>Helicobacter pylori</i> HopQ outermembrane protein inhibits immune cell activities
Stromal Cell-Derived Factor 1 Mediates Immune Cell Attraction upon Urinary Tract Infection
NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7
Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
Targeting Natural Killer Cell Reactivity by Employing Antibody to NKp46: Implications for Type 1 Diabetes
“Messieurs, c'est les microbes qui auront le dernier mot”: Gentlemen, it is the microbes who have the last word (Louis Pasteur)—<i>Fusobacterium nucleatum</i>protect tumors from killing by immune cells
NK Cell Receptor NKp46 Regulates Graft-versus-Host Disease
Natural Killer Cell-Mediated Host Defense against Uropathogenic E. coli Is Counteracted by Bacterial HemolysinA-Dependent Killing of NK Cells
The Viral KSHV Chemokine vMIP-II Inhibits the Migration of Naive and Activated Human NK Cells by Antagonizing Two Distinct Chemokine Receptors
The Expression of the Beta Cell-Derived Autoimmune Ligand for the Killer Receptor Nkp46 Is Attenuated in Type 2 Diabetes
Direct Recognition of Fusobacterium nucleatum by the NK Cell Natural Cytotoxicity Receptor NKp46 Aggravates Periodontal Disease